5395242026-01-012026-03-315395242026-03-315395242025-03-315395242025-04-012026-03-315395242026-01-012026-03-31in-capmkt:OtherExpenses1Member5395242026-01-012026-03-31in-capmkt:OtherExpenses2Member5395242025-04-012026-03-31in-capmkt:OtherExpenses1Member5395242025-04-012026-03-31in-capmkt:OtherExpenses2Member5395242026-03-31OtherNoncurrentFinancialAssetsDomain15395242026-03-31OtherNoncurrentAssetsDomain15395242026-03-31OtherNoncurrentAssetsDomain25395242026-03-31OtherCurrentFinancialAssetsDomain15395242026-03-31OtherCurrentAssetsDomain15395242026-03-31OtherNoncurrentFinancialLiabilitiesDomain15395242026-03-31OtherCurrentFinancialLiabilitiesDomain15395242026-03-31OtherCurrentFinancialLiabilitiesDomain25395242026-03-31OtherCurrentLiabilitiesDomain15395242026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15395242025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15395242026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15395242025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15395242026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares539524LALPATHLABNOTLISTEDINE600L01024Dr. Lal Path Labs Ltd.Main BoardEquity2025-04-012026-03-312026-04-302026-03-27INRMillionsQuarterlyFourth quarterSingle segmentThe business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations.2026-04-3011:30:002026-04-3015:15:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated70270000002400000007267000000135200000000128800000061000000446000000251900000056660000001601000000016010000002740000005000000279000000013220000000000132200000043000000136500000013130000009000000135600000090000001676000000107.867.85007.867.85i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 30 April, 2026 respectively. The consolidated financial results for the year ended 31 March, 2026 have been audited and for the quarter ended 31 March, 2026 have been reviewed by the statutory auditors of the Company and they have issued an unmodified report thereon. <BR> ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as the Group'). <BR> iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of regulation 33 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India. <BR> iv. Figures for the quarter ended 31 March, 2026 and 31 March, 2025 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the quarter ended 31 December, 2025 and 31 December, 2024 respectively, which were subjected to limited review. <BR> v. During the year ended 31 March 2026, Dr. Lal Pathlabs Limited ("Parent Company") has issued 4,000 equity shares of face value of INR 10 each respectively, on exercise of employee stock options. <BR> <BR> Further, during the year ended 31 March 2026, the Parent Company has issued 183,775 equity shares of face value of INR 10 each , to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022"). <BR> vi. The Board of Directors of the Parent Company at their meeting held on 30 April 2026 has proposed final dividend (subject to the approval of shareholders at the ensuing Annual General Meeting) of INR 4 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2026. The total dividend for the year including the final dividend (subject to the approval of shareholders at the ensuing Annual General Meeting) is INR 20.5 per equity share having face value of INR 10 each. <BR> <BR> The Board of Directors of the Parent Company have approved third interim dividend of INR 3.5 per equity share (face value of INR 10 each) at their meeting held on 30 January, 2026 and this was paid on 16 February,2026. <BR> <BR> The Board of Directors of the Parent Company had approved second interim dividend of INR 7 per equity share (face value of INR 10 each) at their meeting held on 31 October, 2025 which was paid on 17 November,2025. <BR> <BR> The Board of Directors of the Parent Company had approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 31 July, 2025 which was paid on 14 August, 2025 <BR> <BR> The Board of Directors of the Parent Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2025. The same was approved by the shareholders in the Annual General Meeting held on 28 June, 2025 and this was paid on 2 July, 2025. <BR> <BR> vii. During the year ended 31 March 2025, Dr. Lal PathLabs Kenya Private Limited (Wholly Owned Subsidiary), a Company incorporated in the Republic of Kenya, has been dissolved and its name has been struck off, with effect from the date of publication of gazette notification dated September 13, 2024. <BR> <BR> viii. The Hon’ble Allahabad Bench of the National Company Law Tribunal (‘Hon’ble Tribunal’ or ‘NCLT’) sanctioned the Scheme of Amalgamation ('Scheme') between the subsidiaries Paliwal Medicare Private Limited (PMPL) (Transferor Company) and Paliwal Diagnostics Private Limited (PDPL) (Transferee Company) on 3 September, 2024. The appointed date as per Scheme was 1 April, 2021. The Scheme had envisaged transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company.Pursuant to the Scheme becoming effective, the amalgamation had been accounted for under the ‘pooling of interests’ method in accordance with Ind AS 103 “Business Combinations” and the assets, liabilities and reserves of the Transferor Company had been accounted for at their book value, in the books of Transferee Company. <BR> ix. The Board of the Parent Company had earlier noted approval by the board of Suburban Diagnostics India Private Limited ("SDIPL"), a wholly owned subsidiary of the Company for voluntary liquidation of SDIPL under the provisions of Insolvency and Bankruptcy Code, 2016, wherein the business undertaking of SDIPL was sought to be distributed to the Company on a going concern basis. The shareholders of SDIPL at their Extra-Ordinary General Meeting held on 6 February, 2025 also accorded approval for the voluntary liquidation of SDIPL. On 18 March, 2025, the liquidator of SDIPL based on the approved scheme has distributed the entire business undertaking of SDIPL to the Company, on a going concern basis. The Hon’ble National Company Law Tribunal (“NCLT”), Mumbai Bench vide its order dated February 27, 2026, approved dissolution of SDIPL. <BR> <BR> The above distribution resulted in inter-alia recognition of long term service agreements in block of intangible assets in tax books of the Company at fair value on 18 March, 2025. Accordingly, deferred tax credit of INR 408 million has been recognised in statement of profit or loss for the quarter and year ended 31 March 2025. <BR> x. The shareholders of the Parent Company on December 07, 2025 had approved, through postal ballot, the issuance of bonus shares, in the proportion of 1:1, i.e. 1 (One) bonus equity share of Rs.10 each for every 1 (One) fully paid-up equity share held as on the record date. The Board of Director's had fixed December 19, 2025 as record rate. Accordingly, the entity has allotted 8,37,75,510 bonus equity shares on December 22, 2025 by capitalizing share premium. In accordance with the 'Ind AS 33 - Earnings per Share', the figures of Earnings Per Share for the year ended March 31, 2025 have been restated to give effect to the allotment of the bonus shares. <BR> xi. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, (‘Labour Codes’) which consolidate twenty-nine existing labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes, amongst other things, introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Group has assessed and estimated the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by 301 Million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Group has presented this incremental amount as “Impact of Labour Codes” under “Exceptional Item” in the Consolidated Statement of Profit and Loss for the three months ended December 31, 2025. The Group continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of liability pertaining to employee benefits. <BR> xii. As at 31st March,2026, the Parent company has the following subsidiaries: <BR> Subsidiaries <BR> Paliwal Diagnostics Private Limited <BR> Dr. Lal PathLabs Nepal Private Limited <BR> Dr. Lal PathLabs Bangladesh Private Limited <BR> Dr. Lal Ventures Private Limited <BR> PathLabs Unifiers Private Limited <BR> Step-down subsidiaries <BR> Centrapath Labs Private Limited <BR> APRL PathLabs Private Limited <BR> Chanre Laboratory Private Limited <BR> JV/Associate Company- Nil <BR> xiii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015. <BR> xiv. During the year, the company has regrouped manpower cost aggregating to INR 266 million for the year ended 31 March, 2025, INR 80 million for quarter ended 31 December 2025, INR 70 million for the quarter ended 31 March 2025, representing collection and transportation charges carried out through third party from employee benefit expenses to other expenses in line with the nature of contract <BR> xv. Refer to Annexure - A for Statement of Consolidated Assets and Liabilities and Annexure - B for Consolidated Cash Flow Statement <BR> 2025-04-012026-03-31AuditedConsolidated27629000000101300000028642000000534600000000503300000022800000016180000009425000000216500000006992000000-301000000669100000015920000001000000159300000005098000000000050980000005200000051500000005048000000500000005100000000500000001676000000102340600000030.2430.20030.2430.2Fees to collection centers/channel partners1006000000Other expenses1513000000Fees to collection centers/channel partners4024000000Other expenses54010000004838000000550000003280000005482000000191500000010000000000010000002093000000209400000087500000019700000015794000000439000000422600000011070000002428000000666700000018000000558000000150040000000223000000156660000000031460000000167600000023406000000250820000003310000002541300000000001454000000145400000026000000600000000154000000001710000001635000000180600000014720000003278000000420000000738000000710000000450700000000604700000031460000000Other financial assets2093000000Non-current tax assets (net)191000000Other non-current assets6000000Other financial assets558000000Other current assets223000000Lease liabilities1454000000Other financial liabilities936000000Lease liabilities536000000Other current liabilities420000000228000000-77000000-268000000060000000-27000000-800000001350000000-10000000016180000000460000000055000000020000000670000000238000000-1940000000-117000000490000000014200000008111000000000175400000006357000000000000005000000167000000000064000000000000000000006640000000-3154000000-4219000000001860000000000000368000000222600000022800000000-2636000000-4980000000-49800000029260000002428000000Remeasurement of the defined benefit obligations5700000057000000Remeasurement of the defined benefit obligations67000000670000001400000017000000Exchange differences on translation of foreign operations00Exchange differences on translation of foreign operations20000002000000004300000052000000AuditedtrueDeloitte Haskins & Sells LLPtrue2027-07-31